OBJECTIVE To further improve the quality standards of Chinese medicinal materials in the Chinese Pharmacopoeia, and to let the academia and industry understand the basic principles of the revision. It also provides a reference for the revision of the origins of Chinese medicinal materials in the Chinese Pharmacopoeia 2030 Edition.

METHODS Query for the names of the family, genus, species of the Chinese medicinal materials original plants in the Chinese Pharmacopoeia 2025 Edition and those such taxonomic literature as Flora of China(the Chinese version and the English version) as well as related references, and make textual research for the problems found. Also analyse the revision and its justifications on the origins of Chinese medicinal materials in Chinese Pharmacopoeia since the 2010 Edition. Further more, discuss the issues related to the origins of Chinese medicinal materials that were of concern to the academic and industry.

RESULTS There were some differences in Chinese names, Latin scientific names of some plant origins between the Chinese Pharmacopoeia and those in authoritative taxonomic literature, and even there were some errors in the Chinese Pharmacopoeia. The revision of the plant origins of Chinese medicinal materials in the Chinese Pharmacopoeia since the 2010 Edition was reasonable, but there were also other problems existing yet.

CONCLUSION The plant origins of Chinese medicinal materials in the Chinese Pharmacopoeia still need to be revised. Further the paper puts forward specific revision suggestions to solve problems.